Fresh analysis suggests that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise regimens.
Research printed in a leading health publication shows that while obese people frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals using such medications must be aware of the potential of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment weight in about 18 months.
Weighing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of participants, compared the results of these new drugs with conventional dieting.
The team point out that individuals who shed pounds through dieting generally experience a slower weight regain—approximately 100 grams monthly—after stopping.
Understanding the Rapid Regain
Nutrition scientists propose the way of the injections accounts for the heightened weight return.
These medications copy a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Issue?
The NHS recommend the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts contend that, given the likelihood of weight regain, the treatment might need to be long-term.
This view is supported by drug manufacturers, who note that the results "underscore the chronic character of obesity," similar to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the medication report a sudden return of hunger.
"It was like a switch flipping and you become ravenous," described a patient.
This challenge is worsened if patients have not adopted lasting dietary or behavioural modifications during treatment.
Growing Adoption
Recent estimates indicate that a significant number of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is higher among females than males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent solution and long-term success hinges on integrated lifestyle management.
